By: Fanny Tzelepis Scientific collaboration is increasingly prevalent. Important advances in areas such as cancer biotherapeutics have resulted from combined efforts, complementary knowledge, and technology transfer. When I joined Dr. Jean-Simon Diallo’s laboratory, the immunotherapeutic properties of oncolytic virus were already apparent. In particular, the ability of oncolytic viruses to boost antigen-specific T cells… Read more »
Category: News
Ottawa Scientists Cure Aggressive Breast Cancer in Mice with Combination Therapy
By: The Ottawa Citizen A new Ottawa research study shows that “triple negative” breast cancer — a particularly aggressive form of the disease — can be successfully treated in mice with a combination of immunotherapies that weaponize the immune system in different ways. The study was published Wednesday in Science Translational Medicine, a… Read more »
The Ottawa Regional Cancer Foundation Invests $100,000 in BioCanRx Research Projects
By: Andrew Duffy, The Ottawa Citizen The Ottawa Regional Cancer Foundation has invested $100,000 in local research aimed at treating leukemia and abdominal tumours with a cancer-fighting vaccine. The money will go toward two Ottawa research projects being sponsored by BioCanRx, a federally-funded, not-for-profit organization dedicated to accelerating the development of cancer immunotherapies… Read more »
Put Another Arrow in the Quiver
New immunotherapy offers hope for glioblastoma patients By: Heather Blumenthal Of all the opponents in the battle against cancer, glioblastoma (GBM), an adult form of brain cancer, is among the worst. Treatment can look initially successful, but often within months, when this “honeymoon” period ends, patients are back with a recurrence. “The… Read more »
Learning Institute Community Dissemination Report 2017
The participants of the 2017 BioCanRx-Cancer Stakeholder Alliance Learning Institute wish to share their Community Dissemination Report with the oncology patient and researcher community, BioCanRx, the Cancer Stakeholder Alliance, and the general public. In this report, you will find the key research take-away messages and the Learning Institute’s group reflections on the topics listed below… Read more »
Lasting Impacts of The Learning Institute
By: Kathy Brodeur-Robb, Executive Director, C17 Council With input from Gabrielle Siegers, Research Associate, Department of Experimental Oncology, University of Alberta, and Brittany Umer, Graduate Student, Dep’t of Medical Microbiology & Immunology, University of Alberta. BioCanRx invited participants from the Cancer Stakeholder Alliance to help develop the BioCanRx Learning Institute. “Sure!” I said; it… Read more »
BioCanRx’s 2016-2017 Annual Report is Now Available
Accelerating the Development of Promising Immunotherapies We are proud to present our annual report on BioCanRx’s many achievements in its second full year of operation. The 2016-2017 year marked a number of milestones for our pan-Canadian network. BioCanRx’s strong research program ramped up and funded 16 new projects including an investment to develop clinical Chimeric… Read more »
Dr. John Bell Receives Canadian Cancer Research Alliance Award
Outstanding Achievements in Cancer Research Dr. John Bell, BioCanRx’s Scientific Director, today received an award for Outstanding Achievements in Cancer Research from The Canadian Cancer Research Alliance at The Canadian Cancer Research Conference in Vancouver. Dr. Bell’s work, his ground-breaking scientific discoveries and his commitment to enabling translational research have made him a pioneer… Read more »
Cancer Clinical Trials Webinar for Cancer Coaches
BioCanRx, Network of Networks and Ottawa Regional Cancer Foundation Release Webinar about Cancer Clinical Trials OTTAWA, ON – November 1, 2017 – BioCanRx, Network of Networks (N2) and the Ottawa Regional Cancer Foundation are excited to announce the release of a collaborative Cancer Clinical Trials Webinar. Originally designed and developed as a training tool… Read more »
